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Prostate cancers, like many other types of cancer, express elevated levels of fatty acid synthase (FASN) to make more fatty acids, which
are required for energy, signaling, and proliferation. Because inhibition of FASN has been shown to sensitize tumors to chemotherapy
and radiation, we studied the effect of C75, a radiosensitizing FASN inhibitor, and compared its single agent and radiosensitizing
activities in 2 prostate cancer cell lines, PC3 and LNCaP, with alternative FASN inhibitors that have progressed into clinical trials. We
also investigated the effect of serum and fatty acid supplementation on responses to FASN inhibitors, probing expression of key proteins
related to fatty acid uptake in response to FASN inhibition, irradiation, and serum lipid concentration and how this may be modulated to
increase the potency of C75. We demonstrated that C75 was the only FASN inhibitor to sensitize cells to ionizing radiation; no
sensitization was apparent with FASN inhibitors TVB-3166 or Orlistat. The prostate cancer cell lines were able to take up fatty acids
from the culture medium, and the availability of fatty acids affected sensitivity of these cells to C75 but not the other FASN inhibitors
tested. C75 also increased expression of fatty acid transporter proteins FATP1 and CD36. Furthermore, blocking CD36 with antibody
increased the sensitivity of cells to C75. We suggest that the potency of C75 is affected by fatty acid availability and that the
effectiveness of FASN inhibitors in combination with ionizing radiation can be further enhanced by regulating fatty acid uptake.
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Prostate cancer is the most commonly diagnosed ma-
lignancy in men and the second leading cause of cancer-
related deaths in men in industrialized countries. Many
common human cancers, including prostate carcinoma,
have elevated levels of lipogenesis and express high
levels of enzymes associated with fatty acid synthesis
compared with normal human tissues.1,2 This increased
lipogenesis, possibly regulated by androgens, is an early
event in the development of prostate cancer3 and corre-
lates with unfavorable prognosis and poor survival. Thecan Society for Radiation Oncology. This is an open access article under
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long-chain fatty acids from the precursors acetyl-CoA and
malonyl-CoA is fatty acid synthase (FASN). Most human
tissues, except liver and adipose tissue, preferentially use
circulating dietary fatty acids, and therefore FASN is
expressed at low levels in these tissues. However,
elevated expression of this enzyme in tumors is associated
with proliferation, resistance to apoptosis, and increased
metastasis.4
Inhibition of FASN has been shown to decrease cancer
cell proliferation, increase apoptosis, and delay tumor
growth in experimental models.5-7 Cerulenin is a FASN
inhibitor that is cytotoxic to cancer cells in vitro but lacks
systemic activity in vivo.8 Synthetic derivatives of
cerulenin, such as the competitive irreversible FASN
inhibitor C75 (a-methylene-b-butyrolactone), have been
developed, and they display anti-tumor activity in pre-
clinical models.9 However, progress to the clinic of FASN
inhibitor drugs has been hampered by poor pharmacoki-
netics and associated side effects, particularly weight loss
and anorexia, which limit their potential for the treatment
of patients with cancer.10,11
Radiation therapy is an effective and well-tolerated
treatment option for many patients with prostate cancer.
However, resistance is common and may be overcome by
combining radiation therapy with radiosensitizing agents.
Similar to the chemosensitization by FASN inhibitors
when administered in combination with anti-cancer
drugs,12,13 previous studies have demonstrated that FASN
inhibition can sensitize cancer cells to radiation therapy in
experimental models.14-16 However, there are currently no
FASN inhibitors that are clinically approved for use in
cancer therapy and the radiosensitizing ability of FASN
inhibitors in clinical trials has not been fully evaluated.
Although Orlistat is a FASN inhibitor that is approved
only as an anti-obesity drug, it has also been shown to
affect cancer cells. It decreased proliferation and induced
apoptosis in prostate cancer cell lines PC3 and LNCaP
and inhibited growth of PC3 and LNCaP xenograft
tumors without affecting proliferation and survival of
non-tumor cells.16,17 Orlistat has also been shown to
inhibit angiogenesis and metastasis in preclinical
models18,19 and appears to sensitize prostate cancer cells
to radiation therapy in a xenograft model of prostate
cancer.16
Saginet Biosciences (formerly 3-V Biosciences)
(TVB) has developed a series of imidazopyridine com-
pounds20 that selectively inhibit FASN and that demon-
strated anti-tumor activity in preclinical models. One of
these compounds, TVB-2640, has become the first FASN
inhibitor to enter clinical trials for patients with cancer,
and initial reports have demonstrated encouraging re-
sponses in patients with non-small cell lung, ovarian, and
breast cancer.21 TVB-3166 and its analogs, TVB-3644
and TVB-3693, decreased proliferation, increased
apoptosis, regulated signaling pathways associated withproliferation and survival, and decreased growth in mul-
tiple tumor cell lines and patient-derived xenografts.22-24
In studies using 22Rv1 prostate cancer cells, TVB-3166
induced apoptosis, reduced growth, and enhanced the
anti-tumor effect of taxanes in a xenograft model.24,25
Therefore, we intended to assess the ability of this
FASN inhibitor to sensitize prostate cancer cells to radi-
ation in our models.
In an attempt to overcome the side effects associated
with C75, enantiomers of this drug have been developed.
It was shown that the (-)-C75 enantiomer was responsible
for the anti-tumor properties, whereas (þ)-C75 induced
the anorectic effects associated with the commonly used
racemic mixture, ()-C75.26 Cytotoxicity of the (-)-C75
enantiomer was also similar to ()-C75 in PC3 and
LNCaP, and importantly, the radiosensitizing properties
of (-)-C75 were similar to those of ()-C75,27 indicating
that it may be possible to retain the anti-tumor and
radiosensitizing effects of this drug while preventing the
unwanted weight loss. This highlights the importance of
understanding the mechanisms by which C75 induces
radiosensitization and whether other FASN inhibitors
have similar effects when directly compared in the same
models.
In addition to increasing the specificity of FASN
inhibitors for clinical application, mechanisms by which
cancer cells are resistant to these agents should also be
investigated. It is becoming evident that uptake of exog-
enous lipids from the tumor microenvironment plays an
important role in disease progression and resistance to
treatment. Indeed, it has recently been demonstrated that
fatty acid uptake is increased in prostate cancer cells
compared with non-tumor tissue,28 and expression of fatty
acid transporters is regulated by androgens.29 Accord-
ingly, the therapeutic potential of targeting both lipid
uptake and lipogenesis has been proposed. Therefore, we
sought to compare the cytotoxicity and radiosensitizing
ability of FASN inhibitors and investigate whether this
was affected by exogenous fatty acid availability and the
expression of fatty acid transporters.Methods and Materials
Reagents
All cell culture media and supplements were purchased
from Life Technologies (UK) unless stated otherwise. All
chemicals, drugs, and oleic acid-bovine serum albumin
solution were from Sigma-Aldrich (UK). Stock solutions
of drugs were prepared in dimethyl sulfoxide (DMSO).
Vehicle control treatments contained DMSO in culture
medium. For antibody treatments, 10 mg/mL CD36
blocking antibody (mouse monoclonal; Santa Cruz
Biotechnology, Germany) or control antibody (mouse
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used.
Tissue culture
Human prostate cancer cell lines, PC3 and LNCaP,
were obtained from American Type Culture Collection
(Manassas, VA) and were used in this study for less than
6 months after resuscitation. PC3 cells were maintained in
Ham’s F-12K medium supplemented with 10% (v/v) fetal
bovine serum (Autogen Bioclear, Wiltshire, United
Kingdom), 2 mM L-glutamine, 0.1 mM sodium pyruvate,
and 50 mg/mL gentamicin. LNCaP cells were maintained
in RPMI 1640 medium supplemented with 10% (v/v)
fetal bovine serum (Hyclone; Fisher Scientific,
United Kingdom), 1% (v/v) hydroxyethyl piper-
azineethanesulfonic acid (HEPES buffer), 1% (v/v) D-
glucose, 1 mM sodium pyruvate, 4 mM L-glutamine, and
50 mg/mL gentamicin.
For comparison, human neuroblastoma SK-N-BE(2c)
and MCF7 cells were purchased from the American Type
Culture Collection, and UVW glioma cells were obtained
from the CRC Beatson Laboratories Medical Oncology
Department in Glasgow, United Kingdom.30 SK-N-
BE(2c) cells were maintained in Dulbecco’s modified
Eagle medium containing 15% (v/v) serum and 2 mM
L-glutamine; MCF7 in F12K medium containing 10%
(v/v), 2 mM L-glutamine, 0.1 mM sodium pyruvate, and
50 mg/mL gentamicin; and UVW in minimal essential
medium containing 10% (v/v) serum and 2 mM
L-glutamine.
MTT cytotoxicity assay
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) reduction assay was used to determine
cell viability. LNCaP and PC3 cells were seeded in 96-
well plates and incubated at 37oC, 5% CO2 to allow
exponential growth. Medium was then replaced by fresh
medium containing drugs, oleic acid, or antibodies at the
required concentrations in triplicate wells. MTT was
added to a final concentration of 0.5 mg/mL and incu-
bated for 2 hours. Cells were then solubilized by addition
of DMSO and the absorbance read at 570 nm using a
Tecan M2000 plate reader.
Clonogenic assay
Cells were seeded in 25 cm2 flasks at 105 cells/flask.
When cultures were in exponential growth phase, medium
was removed and replaced with fresh medium (including
1% or 10% serum) containing drug. For radiation treat-
ment, cells were irradiated using an X-Strahl RS225 x-ray
irradiator (Xstrahl Limited, Surrey, United Kingdom) at a
dose rate of 1.6 Gy per minute. Cells were then incubatedfor 24 h at 37oC in 5% CO2. After treatment, cells were
counted and seeded for clonogenic survival assay as
previously described.15 Cells were incubated at 37C in
5% CO2 for up to 13 days. LNCaP cells did not form
clonogens under similar conditions and so were not used
for clonogenic assay. Colonies were fixed in methanol,
stained with crystal violet solution, and colonies of at least
50 cells were counted.
Immunoblotting
PC3 and LNCaP cells were cultured in monolayers in 25
cm2 flasks for 3 days. Cells were then treated for 24 h before
protein was extracted in lysis buffer containing protease
and phosphatase inhibitors. Whole cellular protein extracts
were resolved in reducing and denaturing conditions by
sodiumdodecyl sulfate polyacrylamide gel electrophoresis.
Proteins were transferred onto polyvinylidene difluoride
Immobilon-P membranes (Merck Millipore, United
Kingdom). Membranes were blocked with 7.5% (w/v)
nonfat dried milk before incubation with the primary anti-
bodies overnight at 4C. Antibodies against b-actin
(Ab8224) and FATP1 (Ab69458) were obtained from
Abcam, United Kingdom. Antibody against CD36 (sc-
7309) was obtained from Santa Cruz Biotechnology.
Membranes were then washed and incubated at room
temperature for 1 hour with horseradish peroxidase-
conjugated secondary anti-mouse antibody (Cell
Signaling Technology, United Kingdom) to enable
chemiluminescent detection using enhanced chem-
iluminescence (ThermoFisher Scientific, United
Kingdom), and images were obtained using Image Lab
software.
Fatty acid uptake
Cells were seeded at a density of 1000 cells per well in
96-well plates and incubated in 37⁰C, 5% CO2 for 3 days.
Medium was removed and replaced with oleic acid bound
to bovine serum albumin in phosphate buffered saline
(Sigma-Aldrich) for up to 72 hours. MTT absorbance was
measured every 24 hours. Accumulation of lipids after 24 h
was determined by Oil Red O staining. Briefly, medium
was removed and cells washed with phosphate buffered
saline before fixing with 10% paraformaldehyde. The cells
were pre-treated with 60% isopropanol and then stained
with 0.2% (w/v) Oil Red O (Sigma-Aldrich) in 60% iso-
propanol. Cells were then washed and photographed under
the microscope. To solubilize, 100% isopropanol was
added before reading absorbance at 492 nm.
Statistics
The number of experimental repeats is provided in
figure legends, and the data are presented in graphs as
A B
C
Figure 1 Cytotoxic effect of inhibitors of fatty acid synthase. Reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide assay of (A) PC3 cells and (B) LNCaP cells after 24-hour exposure to C75, TVB-3166, or Orlistat. Data are means  standard
error of the mean (SEM), n Z 3. (C) Representative images of PC3 and LNCaP cells after 24-hour treatment with control dimethyl
sulfoxide (DMSO) or fatty acid synthase (FASN) inhibitors (50 mM drug) in medium containing 10% serum. Bars represent 200 mm.
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results were analyzed using GraphPad Prism statistical
software using Student t test or 1-way analysis of vari-
ance. A P value of .05 was considered significant and
.01 highly significant.Results
FASN inhibitors are cytotoxic to prostate cancer
cell lines
The effect of 3 FASN inhibitors on viability of 2
prostate cancer cell lines, PC3 and LNCaP cells, was
assessed using the MTT assay. When measured 24 hours
after administration, cell viability was decreased in a
concentration-dependent manner by all 3 FASN inhibitors
(C75, TVB-3166, and Orlistat) in both PC3 and LNCaP
cells, with Orlistat being the least potent (Fig 1A, B). The
drugs induced distinct effects on cell morphology, with
Orlistat and TVB-3166 causing cells (especially LNCaP)
to become flattened, larger, and more granular (Fig 1C).In contrast, C75 treatment caused cells to round up and
develop processes.
Radiosensitizing effect of FASN inhibitors
The effect of C75 on the radiation survival curve of
PC3 prostate cancer cells is shown in Figure 2A, and the
dose enhancement ratio at 50% clonogenic kill was
calculated as 1.84  0.21. These observations indicate
radiosensitization by C75. The radiation-enhancing ac-
tivity of C75 was also demonstrated in breast cancer
(MCF7), glioma (UVW), and neuroblastoma cell lines
(SK-N-BE[2c]) (Fig 2B) by showing supra-additive clo-
nogenic kill after simultaneous administration of x-rays
and C75. To evaluate the ability of alternative FASN
inhibitors to sensitize prostate cancer cells to radiation,
clonogenic assays were carried out on PC3 cells 24 hours
after simultaneous administration of x-rays and TVB-
3166 (Fig 2C) or Orlistat (Fig 2D). Neither TVB-3166
nor Orlistat (at concentrations of 30 and 50 mM) signifi-
cantly enhanced the radiation-induced decrease in clono-
genic survival, suggesting they were not acting in a
similar manner to C75.
A B
C D
† †
Figure 2 Combination of drugs with ionising radiation. (A) Clonogenic assay of PC3 cells 24 hours after simultaneous administration
of x-rays and C75 (30 mM). (B) Clonogenic assay of PC3 (prostate cancer), MCF7 (breast cancer), UVW (glioma), and SK-N-BE(2c)
(neuroblastoma) cells 24 hours after simultaneous administration of x-rays (2 Gy) and C75 (35 mM). Data are means  standard error of
the mean (SEM), n Z 3. )P < .05 and yP < .01 compared with single agent treatments. Clonogenic assay of PC3 cells 24 h after
simultaneous administration of x-rays and (C) TVB-3166 or (D) Orlistat.
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Because serum is a source of fatty acids, we further
assessed differences in the response of prostate cancer
cells to FASN inhibitors by carrying out experiments in
reduced serum (1%) medium, thus reducing the avail-
ability of fatty acid. Compared with experiments carried
out in 10% serum-containing medium, the number of
clonogens was not affected by culture in 1% serum-
containing medium for 24 hours before replating for
clonogenic assay (Fig 3A). Similarly, alterations in serum
level did not significantly affect the clonogenic kill of
PC3 cells induced by administration of x-rays (Fig 3B).
In contrast, MTT assays demonstrated that alteration of
serum levels significantly affected activity of both the
racemic mixture of C75 () and the (-)-C75 enantiomer in
both PC3 and LNCaP cells (Fig 3C, D), with cytotoxicitybeing more pronounced in cells cultured in medium
containing 1% serum. As (-)-C75 had almost identical
effects to ()-C75, the racemic mixture was used in
further experiments. Although addition of oleic acid to
1% serum medium had no direct effect on cell viability, it
was sufficient to prevent C75-induced cytotoxicity in both
PC3 and LNCaP cells (Fig 3E, F) to the level observed
when cells were exposed to C75 in 10% serum medium.
These effects were confirmed by clonogenic assays in
PC3 cells (Fig 3G).
In contrast to the effects on C75 activity, culture in low
(1%) serum-containing medium led to only a small in-
crease in TVB-3166-induced cytotoxicity in either PC3 or
LNCaP cells (Fig 4A, B). Also, addition of oleic acid did
not prevent the cytotoxicity induced by TVB-3166 in 1%
serum medium (Fig 4C, D). Orlistat at a concentration of
50 mM had little cytotoxic effect on either PC3 or LNCaP
†
†
†
†
†
†
Figure 3 Serum concentration affects sensitivity to C75. (A) Clonogenic assay of PC3 cells after 24-hour culture in serum containing
low (1%) or normal (10%) serum. (B) Surviving fraction of PC3 cells in clonogenic assay carried out 24 hours after exposure to x-rays
(1 or 2 Gy). No significant difference was observed between treatments in 1% or 10% serum. 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide assay of (C) PC3 cells and (D) LNCaP cells 24 hours after treatment with C75 administered as either the
racemic mixture () or the (-) enantiomer in medium containing 1% or 10% serum. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenylte-
trazolium bromide assay of (E) PC3 and (F) LNCaP cells was also carried out in 1% serum-containing medium with the addition of oleic
acid-bovine serum albumin solution (100 mM oleic acid) and compared with the effect of C75 (50 mM) in 10% serum-containing
medium. (G) Clonogenic assay of PC3 cells 24 h after culture in medium containing 1% or 10% serum or 1% serum with oleic
acid (100 mM) with and without C75 (35 mM). Data are expressed compared with vehicle treated controls and are means  standard
error of the mean (SEM), n Z 3, except (G) n Z 4. )P < .05 and yP < .01 compared with C75 in 1% serum-containing medium.
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concentration from 10% to 1% (Fig 4E).Fatty acid uptake is regulated by availability
To further investigate whether the serum-dependent
effects on cells and sensitivity to C75 were caused by
differences in the fatty acid availability, we investigated
the expression of proteins known to transport fatty acids
into cells, fatty acid transporter 1 (FATP1), and CD36.
Expression of both transporters was observed in PC3 and
LNCaP cells cultured in serum-free (0%) or low (1%)
serum, and decreased when cultured in normal (10%)
serum (Fig 5A). Expression was also affected by treat-
ment, with C75 increasing FATP1 and CD36 in both PC3
and LNCaP cells and x-rays inducing less marked upre-
gulation (Fig 5B). Cells were able to respond to alter-
ations in availability of fatty acids in medium, with Oil
Red O staining indicating that both cell lines were able to
take up and store fatty acids when the medium was sup-
plemented with oleic acid (Fig 5C); this occurred in a
concentration-dependent manner (Fig 5D). Furthermore,cells responded to increasing fatty acid availability by
increasing proliferation (Fig 5E).Blockage of CD36 enhances cytotoxicity of C75
Although the clonogenic killing effect of x-rays was
not significantly affected by serum concentration (Figs 3B
and 6A), the radiosensitizing effect of C75 was enhanced
in low-serum medium (Fig 6A). To confirm our hypoth-
esis that this was caused by reduced availability and up-
take of exogenous fatty acid, we investigated whether
simultaneous administration of a CD36 neutralizing
antibody would enhance the cytotoxic and radiosensitiz-
ing effect of C75. Neutralizing CD36 antibody decreased
the viability of PC3 cultured in 10% serum medium and
LNCaP cells when administered as a single treatment and
enhanced the cytotoxicity of C75 in an approximately
additive manner (Fig 6B, C). Control antibody (mouse
IgG isotype control) was not cytotoxic (data not shown).
Clonogenic assays in PC3 cells confirmed the potentiating
effect of the CD36 antibody (Fig 6D).
A
D E
B C
Figure 4 Serum concentration does not affect sensitivity to TVB-3166 or Orlistat. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenylte-
trazolium bromide (MTT) assay of (A) PC3 and (B) LNCaP cells 24 h after administration of TVB-3166 in either 1% or 10% serum
medium. (C) PC3 or (D) LNCaP cells were cultured in 1% or 10% serum medium with TVB-3166 (50 mM) and oleic acid (100 mM)
before MTT assay. (E) MTT assay of PC3 and LNCaP cells 24 h after administration of Orlistat in 1% or 10% serum medium. Data are
expressed compared with vehicle treated controls and are means  standard error of the mean (SEM), n Z 3-5.
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Despite our previous demonstration that C75 radio-
sensitizes prostate cancer cells to radiation,15 concerns
remain regarding the clinical application of this drug due
to its unwanted effect on weight loss.10 Although several
FASN inhibitors have been developed that display anti-
cancer properties, it was important to determine whether
more clinically applicable drugs share properties of C75
when directly compared using the same concentrations in
the same models. First, we investigated the cytotoxic
potency of 3 inhibitors of FASN, the cerulenin derivative
C75, the anti-obesity drug Orlistat, and TVB-3166, one of
a series of structurally related FASN inhibitors that in-
cludes TVB-2640, the first-in-human FASN for cancer
clinical trials.21 Phase 1 clinical trials have also recently
demonstrated the safe use of TVB-2640 in men with
metabolic abnormalities.31 Orlistat was the least potent,
with significant cytotoxicity observed in both PC3 and
LNCaP cells around 100 mM, similar to previouslyreported observations in these and other cell lines.14,16
The cytotoxicity of TVB-3166 observed here was
similar to C75 and was previously described at similar
concentrations in bladder cancer cell lines.24 Inhibitors of
FASN differ in their interaction with the enzyme, with
Orlistat inhibiting the thioesterase domain of fatty acid
synthase,17 whereas C75 binds to the b-ketoacyl synthase
domain.8 These distinct effects may be exemplified by
differences in the morphology of the cells after treatment
observed here and previously described for C75 and
Orlistat in LNCaP cells.32
Next, we sought to assess whether the other FASN
inhibitors share with C75 the ability to enhance the
radiation-induced kill of cancer cells. We have previously
described the radiosensitizing effect of C75 in PC3 and
LNCaP cells15 and now demonstrate this in cancer cell
lines originating from breast cancer, glioma, and neuro-
blastoma. However, neither TVB-3166 nor Orlistat
caused any enhancement of the radiation-induced clono-
genic kill. Orlistat has previously been shown to sensitize
only radioresistant (surviving cells from previous
Figure 5 Lipid accumulation and fatty acid uptake in cells. (A) Protein expression of fatty acid transporter 1 (FATP1) and CD36 in
PC3 and LNCaP cells was decreased by culture for 24 h in increased concentrations of serum in medium. (B) FATP1 and CD36
expression was increased by x-rays (2 Gy) and C75 (35 mM) in PC3 and LNCaP cells cultured in medium containing 10% serum.
Representative blots are shown. Loading control was b-actin. (C) Representative images of lipid droplets in PC3 and LNCaP cells
visualized by Oil Red O staining 24 h after culture in medium containing 1% serum with or without oleic acid (100 mM). Bars represent
500 mm. (D) Absorbance of PC3 cells and LNCaP cells exposed to oleic acid for 24 h then stained with Oil Red O. Stain was solubilized
with isopropanol. nZ 3. (E) 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay of PC3 cells every 24 h after culture in
medium containing 1% serum and 100 to 500 mM oleic acid. Data are expressed compared with vehicle treated controls and are means
 standard error of the mean (SEM), n Z 4.
Advances in Radiation Oncology: SeptembereOctober 2020 Enhancing radiosensitization by C75 1001radiation treatment), but not radiosensitive, head and neck
squamous cell carcinoma cells.14 Although Orlistat has
recently been shown to sensitize PC3 and LNCaP cells to
x-rays, this was in a xenograft model, where Orlistat
enhanced the radiation-induced suppression of tumor
growth.16 However, the in vivo effects were only
observed at relatively high doses (240 mg/kg/d), and the
clinical application of Orlistat for cancer therapy is
potentially limited by poor solubility and lowbioavailability.33 In comparable in vitro experiments,
Chuang et al16 demonstrated similar levels of Orlistat
cytotoxicity and x-ray-induced clonogenic kill in PC3
cells to those described here and previously,15 but the
effect of the combination of Orlistat and x-rays on clo-
nogenic kill was not reported. FASN inhibitors from TVB
appear to be safe in humans and reduce lipogenesis in
small clinical studies as a single agent, in addition to
demonstrating some efficacy in patients with cancer.21,31
A B
C D
Figure 6 CD36 blocking antibody enhanced effect of C75. (A) Clonogenic assay of cells cultured for 24 h in medium containing 1%
or 10% serum and treated with x-rays (2 Gy), C75 (35 mM), or a combination of both. )P < .05 between different serum concentrations.
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay of (B) PC3 and (C) LNCaP cells in 10% serum medium after 24 h
treatment with C75 (50 mM) in the absence or presence of CD36 antibody (10 mg/mL). (D) Clonogenic assay of PC3 cells treated in 10%
serum containing medium for 24 h with x-rays (2 Gy), C75 (35 mM), or combination treatment in the absence or presence of CD36
antibody (10 mg/mL). Data are expressed compared with vehicle treated controls and are means  standard error of the mean (SEM), n
Z 3. )P < .05 between presence and absence of antibody.
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cells to chemotherapy,24,25 the radiosensitizing efficacy of
TVB-3166 has not previously been evaluated, and it ap-
pears from the current study that this FASN inhibitor does
not radiosensitize in a similar manner to C75.
Inhibition of FASN may increase dependence on other
components of fatty acid metabolism, including uptake of
fatty acids.34 Therefore, we attempted to enhance the
potency of C75 by modulating availability of exogenous
fatty acids. Culturing in low-serum medium did not affect
cell growth, clonogenic survival, or sensitivity to ionizing
radiation, but markedly enhanced the potency of C75.
Importantly, enantiomers of C75, developed to overcome
the unwanted effects of racemic C75, displayed a similar
serum dependence. Although the tolerability of (-)-C75
has already been reported in vivo,26 the anti-tumor effect
and radiosensitizing effect have yet to be assessed in
animal models. Reduced serum also increased sensitivityto TVB-3166, as previously described in colorectal cancer
cells,22 although this was not as pronounced as with C75.
Monounsaturated fatty acids, such as oleic acid, may
promote proliferation, migration, and invasion of can-
cer cells.35,36 Therefore, we evaluated the effect of
culturing cells in medium containing additional oleic
acid. As expected, we observed that C75-induced
cytotoxicity was rescued by addition of oleic acid.
However, the cytotoxicity induced by TVB-3166 was
not significantly affected by oleic acid supplementation.
Differences between C75 and TVB-3166 may reflect
modulation of different intracellular signalling path-
ways. C75 increases activation of the metabolic sensing
AMP-activated kinase pathway,37 which may also
regulate sensitivity to radiation,38 whereas TVB-3166
affects signalling by disrupting the lipid raft architec-
ture.22 In agreement with our findings with C75,
decreasing monosaturated fatty acid availability by
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of breast cancer cells, and this effect was enhanced in
low-serum condition and rescued by supplementation
with oleic acid.39 Similarly, we showed the prolifera-
tive capacity of PC3 cells was increased in a concen-
tration- and time-dependent manner when fatty acid
availability was increased by addition of oleic acid to
the medium, as also reported for these cell lines and
others when medium is supplemented with oleic acid
or a mixture of oleic acid and palmitic acid.28,36
Uptake of exogenous fatty acids is regulated by alter-
ations in the expression of the FATP family, which con-
tributes to development of a variety of diseases.40 In
particular, FATP1 upregulation in cancer cells plays a
pivotal role in lipid uptake from the microenvironment,
contributing to the proliferation and survival of these
cells, and its inhibition decreases proliferation and inva-
siveness of cancer cells.34,41 The scavenger receptor
CD36 also participates in the internalization of long chain
fatty acids and is highly expressed in tumor, but not
normal, tissues.39,42 This elevated expression leads to
accumulation of lipids, which contribute to cell prolifer-
ation, signal transduction, and fatty acid-induced metas-
tasis, indicating a pro-tumorigenic role for CD36.
Furthermore, higher expression of CD36 has been asso-
ciated with poorer patient prognosis in numerous tumor
types.42-44 The importance of this transporter was also
demonstrated in a study showing that the protective effect
of oleic acid on SCD1 inhibitor-induced cytotoxicity was
prevented by CD36 depletion.39
Although low levels of CD36 protein expression were
observed in untreated cells, this may be due to culture in
medium containing 10% serum, as low expression of
CD36 mRNA was previously reported in LNCaP cells
cultured in a medium containing 5% serum.29 Expression
of both CD36 and FATP1 proteins was, however, upre-
gulated after culture in reduced serum concentrations or
treatment with C75. This is likely in response to the
reduced availability of fatty acids in the medium or the
increased requirement for exogenous fatty acids when
FASN is inhibited and was also observed in response to
AMP-activated kinase activation.37 We also observed
increased expression of CD36 and FATP1 protein after
irradiation, similar to the increase in CD36 and FATP1
mRNA observed in rat liver after irradiation.45
It has been suggested that targeting fatty acid uptake
and transport may be a promising treatment option for
tumors with elevated fatty acid levels, particularly in
combination with drugs affecting lipogenesis.28,39 Knock
down of CD36 using small interfering or short hairpin
RNA, respectively decreased viability and migration of
breast cancer cells in vitro44 and reduced tumor growth in
murine models of glioblastoma and ovarian cancer.42,46
CD36 neutralizing antibodies also inhibited growth of
breast cancer cells,44 metastasis in mouse models of
human oral cancer,43 and cancer severity in patient-derived prostate cancer xenografts.28 Therefore, we
assessed the ability of a CD36 neutralizing antibody to
affect viability and clonogenic survival of prostate cancer
cells, either as a single agent or in combination with C75
or radiation. We demonstrate here that a CD36 neutral-
izing antibody reduced cell viability and clonogenicity as
a single treatment. Crucially, the antibody also enhanced
the effect of C75, similar to the effect observed in human
prostate cancer-derived organoids,28 further supporting
the view that combinations of treatments targeting the
synthesis and uptake of fatty acids may have therapeutic
potential. We also show, for the first time, that although
reducing fatty acid availability or uptake did not enhance
radiation-induced cytotoxicity, the effect of radiation in
combination with a radiosensitizing FASN inhibitor was
enhanced. A similar approach may be possible by tar-
geting FATP1, as suppression of FATP1 was shown to
enhance the pro-apoptotic and anti-proliferative effect of
FASN silencing in liver cancer cells.34
Although Orlistat has been approved as an anti-obesity
drug, it has not been approved for cancer therapy as a
single agent, and our data indicate that it is unlikely to
have potential as a radiosensitizing agent. FASN in-
hibitors from TVB appear to be safe in humans and
reduced lipogenesis in small clinical studies as a single
agent and demonstrate some efficacy in patients with
cancer. However, no radiosensitizing effect was apparent
in this study. C75 had the greatest radiosensitizing effect,
and the use of enantiomers may be a means to overcome
the potential clinical side effects. Our demonstration that
the cancer killing efficacy and radiosensitization of C75
can be further enhanced by combination with inhibitors of
fatty acid uptake may provide a mechanism to increase
the clinical potential of this drug.Conclusions
In summary, we have demonstrated that inhibitors of
fatty acid synthase have distinct effects on cytotoxicity of
prostate cancer cell lines. It appears that not all FASN
inhibitors enhance sensitivity to ionizing radiation at the
concentrations and exposure times used here. We also
observed that C75-induced cytotoxicity is particularly
sensitive to alterations in serum levels and suggest that
this was due to availability of exogenous fatty acids. The
uptake of fatty acids was also regulated by serum levels,
and supplementation of medium with oleic acid increased
its uptake and utilization, rescuing cells from C75-
induced cytotoxicity. Expression of fatty acid trans-
porter proteins is regulated by fatty acid availability, and
blocking CD36-dependent uptake enhanced the sensi-
tivity of prostate cancer cells to inhibition of FASN and a
combination of C75 with radiation, indicating that it
should be considered as an addition to the therapeutic
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